Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats symptomatic obstructive hypertrophic cardiomyopathy (HCM). Sold as Camzyos. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Mavacamten (sold as Camzyos), first approved Apr 28, 2022, with 3 new uses approved and 0 published complete response letters.
First approved: Apr 28, 2022
Applications: 1
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $573M
Orphan exclusivity until: Apr 28, 2029
First approved in the EU: Jun 26, 2023
First approved in Japan: Mar 27, 2025
Safety program: REMS
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 35 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Camzyos, new ingredientDrugs with a new active ingredient indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. · Bristol-Myers Squibb K.K. · Mar 27, 2025 · Review report
Safety Programs (REMS)
FDA requires these when a drug's risks need more than a label: training, enrollment or extra checks before it is prescribed or dispensed
Program
Updated
Camzyos REMSRestricted: prescribers, pharmacies or patients must be certified or enrolled
Sep 30, 2026
Clinical Trials
28 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA